Liraglutide: FDA records on compounded and unapproved products

Has FDA taken action on compounded liraglutide?

Yes. As of Nov 15, 2026, FDA has issued 3 warning letters to 3 companies whose text names liraglutide, the latest dated Jun 8, 2026, and openFDA lists no recall report naming it. FDA announced a proposal not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list, stating it did not identify a clinical need for outsourcing facilities to compound them from bulk drug substances (statement dated Apr 30, 2026).

As of Nov 15, 2026, FDA’s drug shortage data lists 9 presentations of liraglutide with status “Current.”

What FDA has stated, by date

FDA drug shortage status

Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03)Hikma Pharmaceuticals USA, Inc.CurrentOct 14, 2026
Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84)Meitheal Pharmaceuticals, Inc.CurrentAug 27, 2026
Liraglutide, Injection, 6 mg/1 mL (NDC 0480-7250-46)Teva Pharmaceuticals USA, Inc.To Be DiscontinuedMay 14, 2026
Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22)Novo Nordisk, Inc.CurrentSep 22, 2026
Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)Novo Nordisk, Inc.CurrentSep 22, 2026
Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)Novo Nordisk, Inc.CurrentSep 22, 2026
Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)Novo Nordisk, Inc.To Be DiscontinuedAug 25, 2026
Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)Novo Nordisk, Inc.CurrentSep 22, 2026
Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)Novo Nordisk, Inc.CurrentSep 22, 2026
Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85)Meitheal Pharmaceuticals, Inc.CurrentAug 27, 2026
Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)Hikma Pharmaceuticals USA, Inc.CurrentOct 14, 2026

Shortage history, by date

FDA’s words or recordSource
Jul 18, 2023ListedFDA’s shortage data posts Liraglutide Injection (Liraglutide, Victoza, Saxenda) with status “Current,” first posted Jul 18, 2023: 9 presentations.FDA drug shortage data, via openFDA drug shortages endpoint
Feb 21, 2025Status statement“Liraglutide injection : In shortage. Manufacturer has reported two presentations are available, and three have limited availability.”FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
May 14, 2026To Be DiscontinuedFDA’s shortage data posts Liraglutide Injection (Liraglutide) with status “To Be Discontinued,” first posted May 14, 2026: 1 presentation.FDA drug shortage data, via openFDA drug shortages endpoint
Aug 25, 2026To Be DiscontinuedFDA’s shortage data posts Liraglutide Injection (Saxenda) with status “To Be Discontinued,” first posted Aug 25, 2026: 1 presentation.FDA drug shortage data, via openFDA drug shortages endpoint

All GLP-1 drugs on one timeline: shortage history.

FDA adverse event reports (FAERS) listing liraglutide

openFDA’s copy of FDA’s adverse event database holds 40,829 reports that list liraglutide, received from Feb 13, 2004 through Sep 30, 2026. 21,974 (54%) are marked serious by the reporter, including 1,668 that list death as an outcome. No report names a compounded or combination liraglutide product in the product fields, under the rule this index uses. These are unverified reports and do not show that the drug caused any event.

FAERS reports are sent to FDA by drug makers, health professionals and the public. FDA does not verify them, a report does not show that the drug caused the event, and the same event can be reported more than once. Counts reflect how often events were reported, not how often they happen or how risky a drug is. Nothing here is medical advice. Report an error or add a company response.

Reports by year FDA received them

20044
20077
20087
20092
201047
2011120
20121,379
2013837
20141,418
20155,182
20164,708
20173,612
20184,709
20193,273
20202,921
20212,526
20222,034
20232,067
20241,850
20252,215
20261,911

Reaction terms listed most often

Nausea5,03112.3%
Blood glucose increased2,9587.2%
Vomiting2,8366.9%
Diarrhoea2,5996.4%
Off label use1,8894.6%
Pancreatitis1,7374.3%
Headache1,4753.6%
Fatigue1,4313.5%
Decreased appetite1,4163.5%
Drug ineffective1,4163.5%

A report can list several reaction terms. Terms such as “Off label use” or “Incorrect dose administered” describe how the drug was used, not a bodily reaction.

Reports naming a compounded or combination liraglutide product

In openFDA’s public copy of FDA’s adverse event data, checked Nov 15, 2026 and covering reports received through Sep 30, 2026, no report listing liraglutide has product text that names a compounded or combination product, under the rule described below. That is not evidence that no such events were reported: the public data has no compounded flag and no narrative.

A report is counted as naming a compounded product only when one drug entry in it names the drug and that same entry either uses the word “compounded”, “compounding” or “compound” in its product name or dosage text, or lists the drug together with cyanocobalamin, methylcobalamin, pyridoxine, glycine, levocarnitine, carnitine, niacinamide or vitamin B12 or B6 in one product name, a combination no FDA-approved product of these drugs contains. openFDA’s public data has no field that marks a product as compounded and leaves out the report narrative, so this finds only reports whose product text shows it. FDA’s own counts for compounded semaglutide and tirzepatide, from its full internal data, are higher.

Active ingredient (API) imports: FDA import alert and refusal records

FDA’s Import Alert 66-80 Green List (published Oct 9, 2026) has 10 entries naming liraglutide, in China (6), India (2), Denmark (1) and Italy (1); FDA redacts the firm names. FDA’s import refusal records list 4 refused shipment lines whose product code names liraglutide, from Nov 26, 2025 to Sep 18, 2026, most often from Mexico (2), Canada (1) and United States (1); 0 carry an API or powder product code listed on the alert.

Import Alert 66-80 Green List entries naming liraglutide

Product codes and drugs listed
5Redacted by FDACHINA61P[][]76 Liraglutide (Anti-Diabetic)
61P[][]72 Semaglutide (Anti-Diabetic)

61P[][]74 Tirzepatide (Anti-Diabetic)
7Redacted by FDACHINA61P[][]76 Liraglutide (Anti-Diabetic)
61P[][]72 Semaglutide (Anti-Diabetic)

61P[][]74 Tirzepatide (Anti-Diabetic)
8Redacted by FDACHINA61P[][]76 Liraglutide (Anti-Diabetic)
61P[][]72 Semaglutide (Anti-Diabetic)

61P[][]74 Tirzepatide (Anti-Diabetic)
9Redacted by FDACHINA61P[][]76 Liraglutide (Anti-Diabetic)
10Redacted by FDACHINA61P[][]76 Liraglutide (Anti-Diabetic)
61P[][]72 Semaglutide (Anti-Diabetic)

61P[][]74 Tirzepatide (Anti-Diabetic)
13Redacted by FDACHINA61P[][]76 Liraglutide (Anti-Diabetic)
61P[][]72 Semaglutide (Anti-Diabetic)

61P[][]74 Tirzepatide (Anti-Diabetic)
15Redacted by FDADENMARK61P[][]76 Liraglutide (Anti-Diabetic)
61P[][]72 Semaglutide (Anti-Diabetic)
16Redacted by FDAINDIA61P[][]76 Liraglutide (Anti-Diabetic)
18Redacted by FDAINDIA61P[][]76 Liraglutide (Anti-Diabetic)
21Redacted by FDAITALY61P[][]76 Liraglutide (Anti-Diabetic)

Refused liraglutide lines by country and form

Mexico2
Canada1
United States1
Code not listed on Import Alert 66-804

Most recent refused liraglutide lines

Shipment ID
Sep 18, 2026Name not shownUnited States61PDY76 LIRAGLUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80AEK-9731409-8/10001/1
Jan 9, 2026NOVO NORDISK SERV PROF S A DE CVMexico61PDY76 LIRAGLUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80AEK-9134272-3/20003/1
Dec 19, 2025NOVO NORDISK SERV PROF S A DE CVMexico61PDY76 LIRAGLUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80AEK-9048333-8/10003/1
Nov 26, 2025Novo NordiskCanada61PCB76 LIRAGLUTIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80799-0033969-1/20003/1

All firms and countries: Firms on GLP-1 import records.

FDA NDC Directory listings

FDA’s NDC Directory files read Nov 15, 2026 carry 66 listings naming liraglutide: BULK INGREDIENT (34); ANDA (15); BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (5); NDA (5); OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (4); NDA AUTHORIZED GENERIC (2); BLA (1). Outsourcing facility listings: Which outsourcing facilities list compounded semaglutide or tirzepatide with FDA? Every listing: GLP-1 listings in FDA’s NDC Directory. FDA says an NDC “does not in any way denote FDA approval of the product.”

Medicare and Medicaid spending on liraglutide

Medicare Part D spent $329.0 million on liraglutide brands in 2024 (Victoza 3-Pak $203.1 million, Victoza 2-Pak $77.8 million, Liraglutide $48.1 million), before manufacturer rebates, according to CMS. Pharmacies were reimbursed $145.9 million for liraglutide products paid through Medicaid nationwide in 2025, across 262,711 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states.

Medicare Part D, by brand and year

Victoza 3-PakLiraglutide$1,545,815,415$1,422,292,583$1,238,594,872$1,004,635,145$203,063,050
Victoza 2-PakLiraglutide$349,476,159$334,897,957$319,205,509$317,213,565$77,832,721
LiraglutideLiraglutideNo dataNo dataNo dataNo data$48,095,824

Medicaid, nationwide, by year

2020$567,508,684
2021$680,639,494
2022$722,777,322
2023$722,050,605
2024$294,458,438
2025$145,922,324
2026 (Q1)at least $24,183,285

Xultophy (insulin degludec and liraglutide) is counted separately, as a combination product, on the spending page.

Figures are before manufacturer rebates, as CMS reports them. Every GLP-1 drug, CMS’s caveats and each state: Medicare and Medicaid spending on GLP-1 drugs.

FDA warning letters naming liraglutide

Later letters FDA listsLetter
Jun 8, 2026Momentum Health 360 dba Momentum HealthFalse & Misleading Claims/Misbranded (Telehealth)Semaglutide, Tirzepatide, LiraglutideNone listed by FDA as of Nov 15, 2026fda.gov
Feb 20, 2026Kare Solutions, LLC dba ZappyFalse & Misleading Claims/Misbranded (Telehealth)Semaglutide, Tirzepatide, LiraglutideNone listed by FDA as of Nov 15, 2026fda.gov
Feb 20, 2026Levity Inc. dba LevityFalse & Misleading Claims/Misbranded (Telehealth)Semaglutide, LiraglutideNone listed by FDA as of Nov 15, 2026fda.gov

A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.

Recalls naming liraglutide

No openFDA drug recall reports in this index.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.